LONDON (Reuters) - GlaxoSmithKline (L:GSK) said on Wednesday it had hired Kevin Sin from Roche's (S:ROG) Genentech unit to head worldwide business development for pharmaceuticals research and development.
Sin, who will join GSK in San Francisco in July, has been responsible for oncology deal-making at Genentech since 2010. He will play a pivotal role as the British drugmaker seeks to strengthen its drug pipeline through acquisitions and licensing deals.